Skip to main content
Top
Published in: Journal of Clinical Immunology 1/2022

01-01-2022 | Vaccination | Original Article

Vaccination for Patients with Inborn Errors of Immunity: a Nationwide Survey in Japan

Authors: Sho Hosaka, Takahiro Kido, Kazuo Imagawa, Hiroko Fukushima, Tomohiro Morio, Shigeaki Nonoyama, Hidetoshi Takada

Published in: Journal of Clinical Immunology | Issue 1/2022

Login to get access

Abstract

We conducted a nationwide survey of inborn errors of immunity (IEI) in Japan for the second time in 10 years, focusing on protective measures for IEI patients against infectious diseases. Questionnaires were sent to various medical departments nationwide, and a total of 1307 patients were reported. The prevalence of IEI was 2.2 patients per 100,000 population, which was comparable with the previous nationwide study. The most common disease category was autoinflammatory disorders (25%), followed by antibody deficiencies (24%) and congenital defects of phagocyte number or function (16%). We found that a significant number of patients received contraindicated vaccines, principally because the patients were not diagnosed with IEI by the time of the vaccination. Regarding diseases for which BCG vaccination is contraindicated, 43% of patients had actually received BCG, of which 14% developed BCG-related infections. BCG-related infections were mainly observed among patients with CGD and MSMD. In order to prevent IEI patients from receiving inadequate vaccines, continuous education to parents and physicians is needed, along with the expansion of newborn screening, but efforts to screen IEI at the site of vaccination also remain important.
Appendix
Available only for authorised users
Literature
1.
go back to reference Pöyhönen L, Bustamante J, Casanova JL, Jouanguy E, Zhang Q. Life-threatening infections due to live-attenuated vaccines: early manifestations of inborn errors of immunity. J Clin Immunol. 2019;39(4):376–90.CrossRef Pöyhönen L, Bustamante J, Casanova JL, Jouanguy E, Zhang Q. Life-threatening infections due to live-attenuated vaccines: early manifestations of inborn errors of immunity. J Clin Immunol. 2019;39(4):376–90.CrossRef
3.
go back to reference Nunes-Santos CdJ, Rosenzweig SD. Bacille Calmette–Guerin complications in newly described primary immunodeficiency diseases: 2010–2017. Front Immunol 2018;9(1423). Nunes-Santos CdJ, Rosenzweig SD. Bacille Calmette–Guerin complications in newly described primary immunodeficiency diseases: 2010–2017. Front Immunol 2018;9(1423).
4.
go back to reference Yadav RM, Dalvi A, Gupta M, Bargir UA, Shabrish S, Aluri J, et al. Spectrum of inborn errors of immunity in a cohort of 90 patients presenting with complications to BCG vaccination in India. Scand J Immunol. 2021;93(5):e13010.CrossRef Yadav RM, Dalvi A, Gupta M, Bargir UA, Shabrish S, Aluri J, et al. Spectrum of inborn errors of immunity in a cohort of 90 patients presenting with complications to BCG vaccination in India. Scand J Immunol. 2021;93(5):e13010.CrossRef
5.
go back to reference Picard C, Bobby Gaspar H, Al-Herz W, Bousfiha A, Casanova J-L, Chatila T, et al. International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. J Clin Immunol. 2018;38(1):96–128.CrossRef Picard C, Bobby Gaspar H, Al-Herz W, Bousfiha A, Casanova J-L, Chatila T, et al. International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. J Clin Immunol. 2018;38(1):96–128.CrossRef
6.
go back to reference Ishimura M, Takada H, Doi T, Imai K, Sasahara Y, Kanegane H, et al. Nationwide survey of patients with primary immunodeficiency diseases in Japan. J Clin Immunol. 2011;31(6):968–76.CrossRef Ishimura M, Takada H, Doi T, Imai K, Sasahara Y, Kanegane H, et al. Nationwide survey of patients with primary immunodeficiency diseases in Japan. J Clin Immunol. 2011;31(6):968–76.CrossRef
9.
go back to reference Bonilla FA, Khan DA, Ballas ZK, Chinen J, Frank MM, Hsu JT, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015;136(5):1186-205.e1-78.CrossRef Bonilla FA, Khan DA, Ballas ZK, Chinen J, Frank MM, Hsu JT, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015;136(5):1186-205.e1-78.CrossRef
10.
go back to reference Gholam C, Grigoriadou S, Gilmour KC, Gaspar HB. Familial haemophagocytic lymphohistiocytosis: advances in the genetic basis, diagnosis and management. Clin Exp Immunol. 2011;163(3):271–83.CrossRef Gholam C, Grigoriadou S, Gilmour KC, Gaspar HB. Familial haemophagocytic lymphohistiocytosis: advances in the genetic basis, diagnosis and management. Clin Exp Immunol. 2011;163(3):271–83.CrossRef
11.
go back to reference Principi N, Esposito S. Vaccine use in primary immunodeficiency disorders. Vaccine. 2014;32(30):3725–31.CrossRef Principi N, Esposito S. Vaccine use in primary immunodeficiency disorders. Vaccine. 2014;32(30):3725–31.CrossRef
12.
go back to reference Fekrvand S, Yazdani R, Olbrich P, Gennery A, Rosenzweig SD, Condino-Neto A, et al. Primary immunodeficiency diseases and Bacillus Calmette-Guérin (BCG)-vaccine-derived complications: a systematic review. J Allergy Clin Immunol In Practice. 2020;8(4):1371–86.CrossRef Fekrvand S, Yazdani R, Olbrich P, Gennery A, Rosenzweig SD, Condino-Neto A, et al. Primary immunodeficiency diseases and Bacillus Calmette-Guérin (BCG)-vaccine-derived complications: a systematic review. J Allergy Clin Immunol In Practice. 2020;8(4):1371–86.CrossRef
14.
go back to reference Notarangelo L, Casanova J-L, Fischer A, Puck J, Rosen F, Seger R, et al. Primary immunodeficiency diseases: an update. J Allergy Clin Immunol. 2004;114(3):677–87.CrossRef Notarangelo L, Casanova J-L, Fischer A, Puck J, Rosen F, Seger R, et al. Primary immunodeficiency diseases: an update. J Allergy Clin Immunol. 2004;114(3):677–87.CrossRef
15.
go back to reference Migita K, Izumi Y, Jiuchi Y, Iwanaga N, Kawahara C, Agematsu K, et al. Familial Mediterranean fever is no longer a rare disease in Japan. Arthritis Res Ther. 2016;18:175.CrossRef Migita K, Izumi Y, Jiuchi Y, Iwanaga N, Kawahara C, Agematsu K, et al. Familial Mediterranean fever is no longer a rare disease in Japan. Arthritis Res Ther. 2016;18:175.CrossRef
17.
go back to reference Kobrynski L, Powell RW, Bowen S. Prevalence and morbidity of primary immunodeficiency diseases, United States 2001–2007. J Clin Immunol. 2014;34(8):954–61.CrossRef Kobrynski L, Powell RW, Bowen S. Prevalence and morbidity of primary immunodeficiency diseases, United States 2001–2007. J Clin Immunol. 2014;34(8):954–61.CrossRef
18.
go back to reference Rhim JW, Kim KH, Kim DS, Kim BS, Kim JS, Kim CH, et al. Prevalence of primary immunodeficiency in Korea. J Korean Med Sci. 2012;27(7):788–93.CrossRef Rhim JW, Kim KH, Kim DS, Kim BS, Kim JS, Kim CH, et al. Prevalence of primary immunodeficiency in Korea. J Korean Med Sci. 2012;27(7):788–93.CrossRef
19.
go back to reference Rosenberg E, Dent PB, Denburg JA. Primary immune deficiencies in the adult: a previously underrecognized common condition. J Allergy Clin Immunol In Pract. 2016;4(6):1101–7.CrossRef Rosenberg E, Dent PB, Denburg JA. Primary immune deficiencies in the adult: a previously underrecognized common condition. J Allergy Clin Immunol In Pract. 2016;4(6):1101–7.CrossRef
20.
go back to reference Abolhassani H, Azizi G, Sharifi L, Yazdani R, Mohsenzadegan M, Delavari S, et al. Global systematic review of primary immunodeficiency registries. Expert Rev Clin Immunol. 2020;16(7):717–32.CrossRef Abolhassani H, Azizi G, Sharifi L, Yazdani R, Mohsenzadegan M, Delavari S, et al. Global systematic review of primary immunodeficiency registries. Expert Rev Clin Immunol. 2020;16(7):717–32.CrossRef
21.
go back to reference Mahlaoui N, Picard C, Bach P, Costes L, Courteille V, Ranohavimparany A, et al. Genetic diagnosis of primary immunodeficiencies: a survey of the French national registry. J Allergy Clin Immunol. 2019;143(4):1646-9.e10.CrossRef Mahlaoui N, Picard C, Bach P, Costes L, Courteille V, Ranohavimparany A, et al. Genetic diagnosis of primary immunodeficiencies: a survey of the French national registry. J Allergy Clin Immunol. 2019;143(4):1646-9.e10.CrossRef
22.
go back to reference Kallinich T, Gattorno M, Grattan CE, de Koning HD, Traidl-Hoffmann C, Feist E, et al. Unexplained recurrent fever: when is autoinflammation the explanation? Allergy. 2013;68(3):285–96.CrossRef Kallinich T, Gattorno M, Grattan CE, de Koning HD, Traidl-Hoffmann C, Feist E, et al. Unexplained recurrent fever: when is autoinflammation the explanation? Allergy. 2013;68(3):285–96.CrossRef
23.
go back to reference Fliegauf M, Krüger R, Steiner S, Hanitsch LG, Büchel S, Wahn V, et al. A pathogenic missense variant in NFKB1 causes common variable immunodeficiency due to detrimental protein damage. Front Immunol. 2021;12(1327). Fliegauf M, Krüger R, Steiner S, Hanitsch LG, Büchel S, Wahn V, et al. A pathogenic missense variant in NFKB1 causes common variable immunodeficiency due to detrimental protein damage. Front Immunol. 2021;12(1327).
24.
go back to reference Gathmann B, Grimbacher B, Beauté J, Dudoit Y, Mahlaoui N, Fischer A, et al. The European Internet-based patient and research database for primary immunodeficiencies: results 2006–2008. Clin Exp Immunol. 2009;157(Suppl 1):3–11.CrossRef Gathmann B, Grimbacher B, Beauté J, Dudoit Y, Mahlaoui N, Fischer A, et al. The European Internet-based patient and research database for primary immunodeficiencies: results 2006–2008. Clin Exp Immunol. 2009;157(Suppl 1):3–11.CrossRef
25.
go back to reference Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol. 2007;27(5):497–502.CrossRef Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol. 2007;27(5):497–502.CrossRef
26.
go back to reference Sarmiento JD, Villada F, Orrego JC, Franco JL, Trujillo-Vargas CM. Adverse events following immunization in patients with primary immunodeficiencies. Vaccine. 2016;34(13):1611–6.CrossRef Sarmiento JD, Villada F, Orrego JC, Franco JL, Trujillo-Vargas CM. Adverse events following immunization in patients with primary immunodeficiencies. Vaccine. 2016;34(13):1611–6.CrossRef
27.
go back to reference Sohani M, Habibi S, Delavari S, Shahkarami S, Yazdani R, Shirmast P, et al. Evaluation of patients with primary immunodeficiency associated with Bacille Calmette-Guerin (BCG)-vaccine-derived complications. Allergol Immunopathol (Madr). 2020;48(6):729–37.CrossRef Sohani M, Habibi S, Delavari S, Shahkarami S, Yazdani R, Shirmast P, et al. Evaluation of patients with primary immunodeficiency associated with Bacille Calmette-Guerin (BCG)-vaccine-derived complications. Allergol Immunopathol (Madr). 2020;48(6):729–37.CrossRef
28.
go back to reference Marciano BE, Huang CY, Joshi G, Rezaei N, Carvalho BC, Allwood Z, et al. BCG vaccination in patients with severe combined immunodeficiency: complications, risks, and vaccination policies. J Allergy Clin Immunol. 2014;133(4):1134–41.CrossRef Marciano BE, Huang CY, Joshi G, Rezaei N, Carvalho BC, Allwood Z, et al. BCG vaccination in patients with severe combined immunodeficiency: complications, risks, and vaccination policies. J Allergy Clin Immunol. 2014;133(4):1134–41.CrossRef
29.
go back to reference Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA. 1994;271(9):698–702.CrossRef Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA. 1994;271(9):698–702.CrossRef
30.
go back to reference Ohmori M, Ishikawa N, Yoshiyama T, Uchimura K, Aoki M, Mori T. Current epidemiological trend of tuberculosis in Japan. Int J Tuberc Lung Dis. 2002;6(5):415–23.PubMed Ohmori M, Ishikawa N, Yoshiyama T, Uchimura K, Aoki M, Mori T. Current epidemiological trend of tuberculosis in Japan. Int J Tuberc Lung Dis. 2002;6(5):415–23.PubMed
31.
go back to reference Hagiya H, Koyama T, Zamami Y, Minato Y, Tatebe Y, Mikami N, et al. Trends in incidence and mortality of tuberculosis in Japan: a population-based study, 1997–2016. Epidemiol Infect. 2018;147:e38.CrossRef Hagiya H, Koyama T, Zamami Y, Minato Y, Tatebe Y, Mikami N, et al. Trends in incidence and mortality of tuberculosis in Japan: a population-based study, 1997–2016. Epidemiol Infect. 2018;147:e38.CrossRef
32.
go back to reference Puck JM. Newborn screening for severe combined immunodeficiency and T-cell lymphopenia. Immunol Rev. 2019;287(1):241–52.CrossRef Puck JM. Newborn screening for severe combined immunodeficiency and T-cell lymphopenia. Immunol Rev. 2019;287(1):241–52.CrossRef
33.
go back to reference Rechavi E, Lev A, Simon AJ, Stauber T, Daas S, Saraf-Levy T, et al. First year of Israeli newborn screening for severe combined immunodeficiency-clinical achievements and insights. Front Immunol. 2017;8:1448.CrossRef Rechavi E, Lev A, Simon AJ, Stauber T, Daas S, Saraf-Levy T, et al. First year of Israeli newborn screening for severe combined immunodeficiency-clinical achievements and insights. Front Immunol. 2017;8:1448.CrossRef
34.
go back to reference Argudo-Ramírez A, Martín-Nalda A, Marín-Soria JL, López-Galera RM, Pajares-García S, González de Aledo-Castillo JM, et al. First universal newborn screening program for severe combined immunodeficiency in Europe. Two-Years’ Experience in Catalonia (Spain). Front Immunol. 2019;10:2406.CrossRef Argudo-Ramírez A, Martín-Nalda A, Marín-Soria JL, López-Galera RM, Pajares-García S, González de Aledo-Castillo JM, et al. First universal newborn screening program for severe combined immunodeficiency in Europe. Two-Years’ Experience in Catalonia (Spain). Front Immunol. 2019;10:2406.CrossRef
35.
go back to reference Muramatsu H, Kojima D, Okuno Y, Kataoka S, Nakajima Y, Ito T, et al. Combination of TREC measurement and next-generation sequencing in newborn screening for severe combined immunodeficiency: a pilot program in Japan. Blood. 2018;132(Supplement 1):3717.CrossRef Muramatsu H, Kojima D, Okuno Y, Kataoka S, Nakajima Y, Ito T, et al. Combination of TREC measurement and next-generation sequencing in newborn screening for severe combined immunodeficiency: a pilot program in Japan. Blood. 2018;132(Supplement 1):3717.CrossRef
36.
go back to reference Collins CJ, Yi F, Dayuha R, Whiteaker JR, Ochs HD, Freeman A, et al. Multiplexed proteomic analysis for diagnosis and screening of five primary immunodeficiency disorders from dried blood spots. Front Immunol. 2020;11(464). Collins CJ, Yi F, Dayuha R, Whiteaker JR, Ochs HD, Freeman A, et al. Multiplexed proteomic analysis for diagnosis and screening of five primary immunodeficiency disorders from dried blood spots. Front Immunol. 2020;11(464).
37.
go back to reference Boisson-Dupuis S, Bustamante J, El-Baghdadi J, Camcioglu Y, Parvaneh N, El Azbaoui S, et al. Inherited and acquired immunodeficiencies underlying tuberculosis in childhood. Immunol Rev. 2015;264(1):103–20.CrossRef Boisson-Dupuis S, Bustamante J, El-Baghdadi J, Camcioglu Y, Parvaneh N, El Azbaoui S, et al. Inherited and acquired immunodeficiencies underlying tuberculosis in childhood. Immunol Rev. 2015;264(1):103–20.CrossRef
38.
go back to reference Kulkarni M, Desai M, Gupta M, Dalvi A, Taur P, Terrance A, et al. Clinical, immunological, and molecular findings of patients with p47(phox) defect chronic granulomatous disease (CGD) in Indian Families. J Clin Immunol. 2016;36(8):774–84.CrossRef Kulkarni M, Desai M, Gupta M, Dalvi A, Taur P, Terrance A, et al. Clinical, immunological, and molecular findings of patients with p47(phox) defect chronic granulomatous disease (CGD) in Indian Families. J Clin Immunol. 2016;36(8):774–84.CrossRef
39.
go back to reference Toubiana J, Okada S, Hiller J, Oleastro M, Lagos Gomez M, Aldave Becerra JC, et al. Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. Blood. 2016;127(25):3154.CrossRef Toubiana J, Okada S, Hiller J, Oleastro M, Lagos Gomez M, Aldave Becerra JC, et al. Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. Blood. 2016;127(25):3154.CrossRef
40.
go back to reference Lim CK, Abolhassani H, Appelberg SK, Sundin M, Hammarström L. IL2RG hypomorphic mutation: identification of a novel pathogenic mutation in exon 8 and a review of the literature. Allergy Asthma Clin Immunol. 2019;15:2.CrossRef Lim CK, Abolhassani H, Appelberg SK, Sundin M, Hammarström L. IL2RG hypomorphic mutation: identification of a novel pathogenic mutation in exon 8 and a review of the literature. Allergy Asthma Clin Immunol. 2019;15:2.CrossRef
41.
go back to reference Shearer WT, Fleisher TA, Buckley RH, Ballas Z, Ballow M, Blaese RM, et al. Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts. J Allergy Clin Immunol. 2014;133(4):961–6.CrossRef Shearer WT, Fleisher TA, Buckley RH, Ballas Z, Ballow M, Blaese RM, et al. Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts. J Allergy Clin Immunol. 2014;133(4):961–6.CrossRef
Metadata
Title
Vaccination for Patients with Inborn Errors of Immunity: a Nationwide Survey in Japan
Authors
Sho Hosaka
Takahiro Kido
Kazuo Imagawa
Hiroko Fukushima
Tomohiro Morio
Shigeaki Nonoyama
Hidetoshi Takada
Publication date
01-01-2022
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 1/2022
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-021-01160-x

Other articles of this Issue 1/2022

Journal of Clinical Immunology 1/2022 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.